← Back to Search

18F-AraG Imaging for Non-Small Cell Lung Cancer

Phase 1
Recruiting
Led By Dustin Osborne, PhD
Research Sponsored by University of Tennessee
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
This study is open to all adult subjects with histological confirmation of NSCLC enrolled in the parent protocol.
Age 21 years of age or greater
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial is studying how a new T-cell imaging agent moves around the body in patients with non-small cell lung cancer who are getting immunotherapy with or without radiation therapy.

Who is the study for?
Adults diagnosed with non-small cell lung cancer (NSCLC) who are already enrolled in a related study can join. They must be at least 21 years old, have an ECOG performance status of 0-3, and expect to live at least another 24 weeks. Participants need to consent themselves and cannot have severe claustrophobia unless managed by medication.Check my eligibility
What is being tested?
The trial is testing the distribution and movement of a new T-cell imaging agent called 18F-AraG in NSCLC patients. It aims to understand how this agent behaves differently when patients receive immunotherapy alone or combined with radiation therapy.See study design
What are the potential side effects?
Specific side effects for the imaging agent aren't detailed, but participants may experience discomfort from the procedure itself or anxiety if they're claustrophobic. Those with kidney issues or pregnant women are excluded due to potential risks.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Any adult with confirmed non-small cell lung cancer (NSCLC) can participate in the study.
Select...
You are 21 years old or older.
Select...
You are expected to live for at least 24 weeks from the time of screening.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Biodistribution of 18F-AraG
Kinetics of 18F-AraG
Secondary outcome measures
Assessment of biodistribution and kinetics differences between study arms

Trial Design

2Treatment groups
Experimental Treatment
Group I: NSCLC with Immunotherapy without radiationExperimental Treatment1 Intervention
The biodistribution and kinetics of the 18F-AraG compound will be assessed in non-small cell lung cancer patients undergoing immunotherapy without adjuvant radiation therapy
Group II: NSCLC with Immunotherapy with radiationExperimental Treatment1 Intervention
The biodistribution and kinetics of the 18F-AraG compound will be assessed in non-small cell lung cancer patients undergoing immunotherapy with adjuvant radiation therapy

Find a Location

Who is running the clinical trial?

University of TennesseeLead Sponsor
188 Previous Clinical Trials
141,639 Total Patients Enrolled
CellSight Technologies, Inc.Industry Sponsor
17 Previous Clinical Trials
309 Total Patients Enrolled
Dustin Osborne, PhDPrincipal InvestigatorUniversity of Tennessee
1 Previous Clinical Trials
20 Total Patients Enrolled

Media Library

18F-AraG 2023 Treatment Timeline for Medical Study. Trial Name: NCT04052412 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current status of 18F-AraG's approval from the FDA?

"Analyses conducted by Power suggest that 18F-AraG has a safety rating of 1 as it is currently undergoing Phase 1 clinical trials, which means there is minimal evidence regarding its efficacy and safety."

Answered by AI

Are any further participants currently being recruited for this experiment?

"Clinicaltrials.gov attests to the fact that this medical research project is still seeking participants; its initial posting was on July 16th, 2019 and it has been modified most recently on May 12th 2022."

Answered by AI

How many participants are there in this clinical investigation?

"Yes, the clinical trial data present on clinicaltrials.gov confirms that this study is actively recruiting participants. The experimental protocol was first posted on July 16th 2019 and last modified on May 12th 2022; 2 candidates are required to be recruited from a single facility."

Answered by AI
Recent research and studies
~0 spots leftby Mar 2025